280 related articles for article (PubMed ID: 25433360)
1. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
[TBL] [Abstract][Full Text] [Related]
3. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
Tjionas H; Gupta AK
J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028
[TBL] [Abstract][Full Text] [Related]
4. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
[TBL] [Abstract][Full Text] [Related]
5. Management of Carfilzomib-Associated Cardiac Adverse Events.
Mikhael J
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
Shah C; Bishnoi R; Jain A; Bejjanki H; Xiong S; Wang Y; Zou F; Moreb JS
Leuk Lymphoma; 2018 Nov; 59(11):2557-2569. PubMed ID: 29465266
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity with carfilzomib at doses greater than 27 mg/m
Kim GY; Ahuja T; Papadopoulos J; Cirrone F
J Oncol Pharm Pract; 2019 Jan; 25(1):229-233. PubMed ID: 28914153
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib.
Zhao F; Yang B; Wang J; Zhang R; Liu J; Yin F; Xu W; He C
Drug Des Devel Ther; 2018; 12():1525-1531. PubMed ID: 29881259
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
14. Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Wang M; Cheng J
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():24-30. PubMed ID: 25184233
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
16. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
17. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.
Gavazzoni M; Lombardi CM; Vizzardi E; Gorga E; Sciatti E; Rossi L; Belotti A; Rossi G; Metra M; Raddino R
Eur J Pharmacol; 2018 Nov; 838():85-90. PubMed ID: 30201379
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
19. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
[TBL] [Abstract][Full Text] [Related]
20. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
